Member Info for EmeraldCarrots

I presume he looks at it the same sort of way I do. Cellbxhealth have a unique machine that can catch live, intact, uncontaminated circulating tumor cells (CTC's). So if you want to examine some to get UP TO DATE information about a opersons cancer I don't think you could possibly get any better. So many questions. How do we know CTC's are not a BETTER sample than a weeks old or more tissue sample? Or would it be at least good practice to test a number of CTC's to see if they show the cancer has NOT evolved since the tissue sample was taken making the intended treatment possibly useless? Also we know that Cellbxhealth's "dual analysis" for lung cancer finds about TWICE an many cancer biomarkers as CtDna analysis alone.......... The industry needs to snap out of this lethargic snails pace progress and get on with using dual analysis! Lastly Immatics have 3 cancer drug trials going on NOW that use ther Parsortix machine. So are Immatics a bit stupid? I think not. The official news is one of these trials has now moved to phase 3, and another one has moved to phase 2. What more does the market need to get the sp moving North?

Conifer Management LLC 18/12/2025 340,681,394 29.90%

Dermot Keane 18/12/2025 176,110,422 15.46%

Global Frontier Partners, LP 18/12/2025 102,288,946 8.98%

All IMHO.

Stocksaint.

Private hospitals that service the people who do have more money are likely to get on board when you have a World wide market IMHO.

Https://investors.genedrive.com/shareholder-information-1759744374

Louder than words. To me he has not made enough commitment to the Company. The genedrive website indicates he has just a 0.24% share holding. Says it all.

All IMHO.

So, I presume ANY hospital, doctors, or medical facility in the whole World, where the CE mark is accepted as good enough to give usage clearance can order Genedrive machines from the web site. Private chains of hospitals in so called 3rd World Countries that service the needs of the better off parts of thei populations?? The potential market is truly World wide.

A minute! Relatively small income. Never the less the initial sales of the machine, printer and consumables, obvioulsy followed by sales of the consumables for years to come. Hundreds of Genedrive machines to be in use in remote places? All over the World?? Potential here is massive.

https://www.lse.co.uk/rns/GDR/scotland-nhs-8220test-of-change8221-pilot-programme-tvkxvazb4r79kyf.html

https://www.nhsgrampian.org/news/2025/december/nhs-grampian-and-western-isles-stroke-patients-to-benefit-from-rural-healthcare-innovation?fbclid=IwY2xjawOvXIJleHRuA2FlbQIxMABicmlkETFFYXBncHpFaDllYnVvbGJLc3J0YwZhcHBfaWQQMjIyMDM5MTc4ODIwMDg5MgABHirYx23sbquXWwupva-XFue7efpwe2K2EVolD_isqyozeJ3T96rW0zWZfY_0_aem_17u2kZcntbXUEHle2mGklQ

16/12/2025.

https://www.lse.co.uk/rns/AZN/enhertu-approved-in-us-for-1l-her2-metastatic-bc-1tmt8tx7407elmb.html

"Enhertu plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer".

There is no liquid biopsy test I can find to compliment the solid tissue one. Cellbxhealth have previously said their HER2 test had good results. Here is the original RNS:-

https://www.lse.co.uk/rns/AGL/contract-announcement-with-eisai-inc-49aplx5us0gzg6h.html

Breast cancer patients are treated with enhurtu?

===================

A.I.

No, liquid biopsy is not the standard primary method for measuring HER2 levels before starting treatment with Enhertu (trastuzumab deruxtecan) in breast cancer patients; tissue biopsy is the current standard of care.

Current Standard for HER2 Testing

Patient selection for Enhertu is based on HER2 expression as determined by validated tests on tumor tissue samples (from a biopsy or surgery).

The primary method is immunohistochemistry (IHC), which scores HER2 protein levels as 0, 1+, 2+, or 3+.

For equivocal (IHC 2+) results, an in situ hybridization (ISH) test is performed on the tissue to check for gene amplification.

Enhertu is approved for patients across the spectrum of HER2 expression, from HER2-ultralow to HER2-positive (IHC 3+ or IHC 2+/ISH+), depending on the specific cancer type and prior treatments.

The Role of Liquid Biopsy

While tissue biopsy remains the standard, liquid biopsy (a blood test that detects circulating tumor cells or DNA) is an emerging and valuable complementary tool, but generally not used as the sole determinant for initial treatment decisions.

Complementary Tool: Liquid biopsies can provide a broader view of a tumor's molecular profile and can be used for real-time monitoring of HER2 status, which can change over time or between primary and metastatic sites.

"Cancer Biology Research: Viable CTCs isolated through liquid biopsy can be cultured in a laboratory setting to create patient-derived cell lines, which are invaluable tools for understanding the biology of metastasis and screening for new anti-cancer drugs.".

In potential candidates? Can they do a liquid biopsy?

========================

A.I.

Use of Liquid Biopsy

Yes, they are exploring the use of liquid biopsies.

Research and Development: Both companies are co-developing and clinically validating innovative liquid biopsy tests, which detect HER2 genetic amplification and protein expression in circulating tumor cells (CTCs) or circulating tumor DNA (ctDNA) collected from a simple blood draw.

Potential Benefits: Liquid biopsies offer a less invasive way to monitor HER2 status and cancer changes over time, especially since HER2 expression can be heterogeneous across different metastatic sites and can change after treatment.

Current Status: While promising results from studies show that liquid biopsies can correlate with tissue results and track tumor dynamics, these methods are largely still in the clinical validation and research phases and are not yet the standard of care for determining initial treatment eligibility in routine clinical practice. Standard practice still relies on a tumor tissue sample for definitive diagnosis and treatment planning.

Very significant. " Parsortix platform shown to be compatible with the Roche BenchMark ULTRA automated staining system, with initial study of three key drug targets: HER2 (breast), TROP2 (lung) and PSMA (prostate)".

Automating analysis of CTC samples found using Parsortix. Offers Myriad Genetics a way to more quickly analyse parsortix samples. In time the "dual analysis" assays might be added to the machines capabitities!!!! It already supports 250 or so assaya.

=====================

The Roche BenchMark ULTRA is a sophisticated, fully automated system for staining microscope slides in anatomic pathology labs, automating complex processes like baking, deparaffinization, and staining for Immunohistochemistry (IHC) and In Situ Hybridization (ISH). It provides high-quality, consistent diagnostic slides by individually processing up to 30 slides, improving lab efficiency, reducing manual touchpoints, and supporting a vast library of assays for personalized medicine and companion diagnostics.

Key Features & Functions:

Full Automation: Handles baking, deparaffinization, and staining steps, freeing up technologists.

Individual Slide Control: Features 30 independent drawers with controlled heaters and liquid coverslips for precise, customized protocols for each slide.

Workflow Efficiency: Offers a single-piece workflow, allowing access to reagents and waste removal without interrupting ongoing staining runs.

Broad Assay Menu: Supports over 250 ready-to-use assays for IHC, ISH, SISH, immunofluorescence, and multiparameter staining.

Improved Quality: Uses air vortex mixers and controlled heating for uniform reagent distribution and consistent staining.

Enhanced Software (ULTRA PLUS): Includes features like remote connectivity, electronic inventory, and easier navigation for better lab management.

Waste Management: Advanced systems, like the DAB degradation in the PLUS model, meet stringent environmental standards.

Purpose:

It's used by pathologists and lab personnel to detect analytes on tissue samples (like FFPE blocks) to aid in diagnosing diseases, particularly in cancer diagnostics and personalized medicine.

==================

https://www.lse.co.uk/rns/CLBX/cellbxhealth-presents-proof-of-concept-study-dwro0kgms0rwtkg.html

All IMHO.

Significant the buyer paid 1.2p for each share. 6,075,000 shares @ 1.2p = £72,900.00. A big trade by any stretch.

Well, IMHO if they don't land big new deals now they are jointly promoting with Qiagen, with Myriad Genetics working to possibly add liquid biopsy using Parsortix to their range, and working with Illumina on dual analysis for more cancers I'll have to eat my keyboard.

All IMHO.

The thing that strikes me about the Rotunda Hospital in Ireland's order is that the hospital did not order the MT-RNR1 to test it even further (like say the Saudi Arabian hospital). It seems they were happy with whatever testing they looked into (there already has been a lot as we know). Maybe it was the Scottish NHS ordering a whole Country rollout that prompted them to get on with it. Hopefully all the other Irish hospitals with neonatal will follow suit.

=====================

It's easy to imagine orders for the MT-RNR1 absolutey taking off if you ask me. Even if NICE seem to be trying to delay, delay, delay presumably because the NHS in England are skint and they have been told to...... delay delay, delay?? Scotland, Ireland and Saudi Arabia will be leading NHS England by a mile the way things are going, and they helped develop it! NICE are simply NOT..

All IMHO.

Mortalone.

No shares can be issued at the moment without prior shareholder approval. A non-starter for the momenmt.

Executioner.

What is he relevance of your comment? It seems irrelevant babies in Saudi have a hearing test as soon as they are born. I suppose if they are found to be deaf already then they can take the antibiotics as it won't matter! If they are NOT born deaf and need antibiotics then they need to have the MT-RNR1 test to make sure they won't go deaf after taking the antibiotics. Your comment seems irrelevant.

The thing that strikes me about the Rotunda Hospital in Ireland's order is that the hospital did not order the MT-RNR1 to test it even further (like say the Saudi Arabian hospital). It seems they were happy with whatever testing they looked into (there already has been a lot as we know). Maybe it was the Scottish NHS ordering a whole Country rollout that prompted them to get on with it. Hopefully all the other Irish hospitals with neonatal will follow suit.

=====================

It's easy to imagine orders for the MT-RNR1 absolutey taking off if you ask me. Even if NICE seem to be trying to delay, delay, delay presumably because the NHS in England are skint and they have been told to...... delay delay, delay?? Scotland, Ireland and Saudi Arabia will be leading NHS England by a mile the way things are going, and they helped develop it! NICE are simply NOT.

All IMHO.

The thing that strikes me about the Rotunda Hospital in Ireland's order is that the hospital did not order the MT-RNR1 to test it even further (like say the Saudi Arabian hospital). It seems they were happy with whatever testing they looked into (there already has been a lot as we know). Maybe it was the Scottish NHS ordering a whole Country rollout that prompted them to get on with it. Hopefully all the other Irish hospitals with neonatal will follow suit.

All IMHO.

Interesting the Rotunda Hospital in Ireland simply ordered the MT-RNR1 (I assume 2) and are now up and running as per the RNS. Pregnant women in Ireland may be starting to ask if their local neonatal hospital has the MT-RNR1 so babies can be tested to see if they would have a bad reaction to antibiotics rendering the baby deaf! Huge potential in Ireland it seems.

All IMHO.

A.I.

Many major hospitals across Saudi Arabia offer specialized Neonatal Intensive Care Units (NICUs) for critically ill newborns, including large private chains like Saudi German Hospitals, Dr. Soliman Fakeeh Hospital, and government/specialized facilities such as King Abdullah Specialized Children's Hospital (MNGHA), King Faisal Specialist Hospital & Research Centre (KFSHRC), Maternity and Children's Hospitals, and university hospitals like Imam Abdulrahman Bin Faisal University, providing advanced care for preemies, respiratory issues, and congenital conditions.

Key Hospitals with NICUs:

Dr. Soliman Fakeeh Hospital (Jeddah/Madinah): A leading center with significant capacity for neonatal care.

Saudi German Hospitals (Various locations): Offers comprehensive newborn intensive care with specialized teams.

King Abdullah Specialized Children's Hospital (KASCH) (Riyadh - MNGHA): A major regional center, handling complex cases like conjoined twins.

King Faisal Specialist Hospital & Research Centre (KFSHRC) (Riyadh/Jeddah): A leading institution known for advanced healthcare and research.

Dr. Abdulrahman Al-Mishari Hospital (Riyadh): Provides high-level NICU care for premature babies and complex conditions.

Maternity and Children's Hospitals (Various cities like Dammam, Al-Jouf): Ministry of Health facilities dedicated to maternal and pediatric care, often with strong NICUs.

Imam Abdulrahman Bin Faisal University Hospital (Dammam): Features a dedicated Neonatal ICU.